Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retroviruses02:33

Retroviruses

15.3K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.3K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

959
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
959
Viral Recombination00:57

Viral Recombination

25.4K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BLIMP-1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses.

Immunology and cell biology·2026
Same author

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk.

Trials·2026
Same author

Common Acquisition of Broadly Neutralizing Antibodies in an HTLV-1c+ First Nations Cohort from Central Australia.

Viruses·2026
Same author

Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial.

BMJ open·2026
Same author

Characteristics of SARS-CoV-2 transmission in Australia.

Journal of the Royal Society, Interface·2026
Same author

Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2.

Drug delivery and translational research·2026

Related Experiment Video

Updated: Mar 7, 2026

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

12.8K

Differentiating founder and chronic HIV envelope sequences.

John M Murray1, Stephen Maher1,2, Talia Mota3

  • 1School of Mathematics and Statistics, UNSW Sydney, Sydney, New South Wales, Australia.

Plos One
|February 11, 2017
PubMed
Summary

Identifying common features in early HIV founder viruses is key to developing an effective vaccine. This study analyzed Env sequences to find prevalent traits distinguishing founder from chronic HIV strains, aiding future vaccine design.

More Related Videos

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.2K
Determining 3'-Termini and Sequences of Nascent Single-Stranded Viral DNA Molecules during HIV-1 Reverse Transcription in Infected Cells
13:07

Determining 3'-Termini and Sequences of Nascent Single-Stranded Viral DNA Molecules during HIV-1 Reverse Transcription in Infected Cells

Published on: January 30, 2019

9.9K

Related Experiment Videos

Last Updated: Mar 7, 2026

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

12.8K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.2K
Determining 3'-Termini and Sequences of Nascent Single-Stranded Viral DNA Molecules during HIV-1 Reverse Transcription in Infected Cells
13:07

Determining 3'-Termini and Sequences of Nascent Single-Stranded Viral DNA Molecules during HIV-1 Reverse Transcription in Infected Cells

Published on: January 30, 2019

9.9K

Area of Science:

  • Virology and Immunology
  • Bioinformatics
  • Vaccine Development

Background:

  • Developing an effective HIV vaccine remains a significant challenge, despite progress in understanding broadly neutralizing antibodies against the HIV envelope glycoprotein (Env).
  • Identifying conserved features of early founder HIV strains crucial for transmission could greatly facilitate vaccine design.

Purpose of the Study:

  • To identify prevalent distinguishing features between early founder HIV-1 Env sequences and chronic HIV-1 Env sequences using bioinformatic and operations research methods.
  • To analyze common amino acid pair variations in founder strains of subtypes B and C to inform vaccine strategies.

Main Methods:

  • Comparative analysis of 78 subtype B and 55 subtype C founder Env sequences against an equal number of chronic sequences.
  • Utilized optimal network analysis to identify covarying amino acid pairs differentiating founder from chronic strains.
  • Assessed the frequency of specific amino acid pairs and the alpha-4-beta-7 (α4β7) binding site within optimal networks.

Main Results:

  • Identified distinct sets of optimal covarying amino acid pairs separating founder from chronic strains for subtype B (13 pairs) and subtype C (75 pairs).
  • Specific pairs were consistently found in optimal solutions for subtype B, while subtype C showed greater diversity, with no single pair dominating all solutions.
  • The α4β7 binding site was disproportionately represented among optimal pairs, particularly for subtype C, suggesting its potential role in early infection.

Conclusions:

  • The high variability in optimal pairs for subtype C highlights the difficulty of targeting transmission with a single vaccine strain.
  • Specific conserved features in founder Env sequences, including the α4β7 binding site, offer potential targets for novel HIV vaccine strategies.
  • Early transmitted founder sequences often contain specific optimal features, providing insights into critical viral elements for vaccine development.